Abstract 4027
Background
Recent advances in cancer therapies have resulted in a greater number of people receiving chemotherapy in ambulatory care settings worldwide. In Spain emergency departments, is the single point of entry to acute inpatient services, and therefore play a pivotal role in the immediate management of chemotherapy complications. This study set out to explore ED use by ambulatory patients receiving anti-cancer agents in febrile neutropenia episodes. Data will contribute to service innovation for optimal patient care and health service efficiency.
Methods
A 12 month retrospective observational study of unplanned ED presentation by patients within 30 days of receiving anti-cancer therapy for a range of cancer diagnoses.
Results
The preliminary main results are the following. There were 382 ED presentations of chemotherapy related FN in cancer patients and a sample of 170 were selected in regards to a 30-day frame between the FN episode and the chemotherapy administration. The most common diagnoses were breast (33/170; 19.4%); bowel (32/170; 18.8%) and genitourinary cancers (30/170; 17.6%). A total of 145 (145/170; 85.2%) were given a triage level III and the rest (25/170; 14.7%) a triage level II.
Conclusions
There is still some important data to exploit such as median time from triage to medical attention and median time from triage to antibiotic, which will allow the researchers to establish the percentage of compliance with evidence based guidelines. As reported in international literature the compliance is challenging in a busy and unpredictable ED setting. Therefore it will be interesting to measure our compliance rates and explore opportunities to further improve adherence to evidence-based guidelines and aim for better clinical outcomes in case our results correlate with current literature.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Ethic Committee Hospital Clinic Barcelona.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
2108 - Biomarker analyses of ramucirumab in patients with platinum refractory urothelial cancer from RANGE, a global, randomized, double-blind, phase 3 study.
Presenter: Michiel Van der Heijden
Session: Poster Display session 3
Resources:
Abstract
3090 - Comparison of Immuno-Oncology (IO) Biomarkers in Adenocarcinoma (ACB), Urothelial Carcinoma (UCB) and Squamous Cell Carcinoma (SCCB) of the Bladder, with interim results from PURE01
Presenter: Daniele Raggi
Session: Poster Display session 3
Resources:
Abstract
5211 - Potential role of a clinical, taxonomical classification and RNA expression integrated signature to predict response to neoadjuvant platinum-based chemotherapy in muscle-invasive bladder cancer (MIBC) patients
Presenter: Albert Font
Session: Poster Display session 3
Resources:
Abstract
3206 - Hyperphosphatemia due to Erdafitinib (a Pan-FGFR Inhibitor) and Anti-tumor Activity Among Patients (Pts) with Advanced Urothelial Carcinoma (UC)
Presenter: Scott Tagawa
Session: Poster Display session 3
Resources:
Abstract
3110 - Prognostic role of FGFR Mutations and FGFR mRNA expression in metastatic urothelial cancer treated with anti-PD(L1) inhibitors in first and second line setting
Presenter: Florian Roghmann
Session: Poster Display session 3
Resources:
Abstract
3564 - Circulating tumour DNA (ctDNA) utility as a biomarker for metastatic urothelial carcinoma (mUC)
Presenter: Jean-Michel Lavoie
Session: Poster Display session 3
Resources:
Abstract
2760 - Comparative analysis of tumor mutational burden (TMB) prediction methods and its association with determinants of the tumor immune microenvironment of urothelial bladder cancer (UBC)
Presenter: Markus Eckstein
Session: Poster Display session 3
Resources:
Abstract
2513 - The Immunoscore in patients with urothelial carcinoma treated with neoadjuvant chemotherapy: clinical significance for pathological response and survival
Presenter: Elise Nassif
Session: Poster Display session 3
Resources:
Abstract
2835 - Genomic analysis of urothelial cancer and associations with treatment choice and outcome
Presenter: David Sarid
Session: Poster Display session 3
Resources:
Abstract
5763 - cfDNA is an acceptable but insufficient means of characterizing FGFR3 mutation in patients with metastatic urothelial cancer (mUC)
Presenter: Sumanta Pal
Session: Poster Display session 3
Resources:
Abstract